

# Sylvie Lantuejoul

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9245446/publications.pdf>

Version: 2024-02-01

195  
papers

14,819  
citations

17405

63  
h-index

20900

115  
g-index

225  
all docs

225  
docs citations

225  
times ranked

16858  
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. <i>Nature Genetics</i> , 2012, 44, 1104-1110.	9.4	1,186
2	Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). <i>Lancet, The</i> , 2016, 387, 1415-1426.	6.3	790
3	PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1302-1311.	0.5	589
4	The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. <i>Journal of Thoracic Oncology</i> , 2022, 17, 362-387.	0.5	429
5	Ectopic Activation of Germline and Placental Genes Identifies Aggressive Metastasis-Prone Lung Cancers. <i>Science Translational Medicine</i> , 2013, 5, 186ra66.	5.8	392
6	Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. <i>Lancet Oncology, The</i> , 2019, 20, 239-253.	5.1	342
7	TUNEL Apoptotic Cell Detection in Tissue Sections: Critical Evaluation and Improvement. <i>Journal of Histochemistry and Cytochemistry</i> , 1998, 46, 327-334.	1.3	320
8	Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1223-1230.	0.8	300
9	Preoperative Circulating Tumor Cell Detection Using the Isolation by Size of Epithelial Tumor Cell Method for Patients with Lung Cancer Is a New Prognostic Biomarker. <i>Clinical Cancer Research</i> , 2011, 17, 827-835.	3.2	281
10	Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. <i>Nature Communications</i> , 2018, 9, 1048.	5.8	254
11	SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas. <i>Nature Genetics</i> , 2015, 47, 1200-1205.	9.4	252
12	CD74- <i>NRG1</i> Fusions in Lung Adenocarcinoma. <i>Cancer Discovery</i> , 2014, 4, 415-422.	7.7	238
13	Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection. <i>Journal of Clinical Oncology</i> , 2015, 33, 3439-3446.	0.8	234
14	A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1599-1610.	0.5	234
15	Pulmonary Veno-occlusive Disease and Pulmonary Capillary Hemangiomatosis. <i>American Journal of Surgical Pathology</i> , 2006, 30, 850-857.	2.1	223
16	Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 377-407.	0.5	212
17	Loss of Histone H4K20 Trimethylation Occurs in Preneoplasia and Influences Prognosis of Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 7237-7245.	3.2	209
18	The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. <i>Lung Cancer</i> , 2012, 76, 1-18.	0.9	206

#	ARTICLE	IF	CITATIONS
19	PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020, 15, 499-519.	0.5	203
20	Dual IHC and FISH Testing for ALK Gene Rearrangement in Lung Adenocarcinomas in a Routine Practice: A French Study. <i>Journal of Thoracic Oncology</i> , 2012, 7, 348-354.	0.5	197
21	Neural Cell Adhesion Molecules (NCAM) and NCAM-PSA Expression in Neuroendocrine Lung Tumors. <i>American Journal of Surgical Pathology</i> , 1998, 22, 1267-1276.	2.1	192
22	Definition of Synchronous Oligometastatic Non-“Small Cell Lung Cancer” A Consensus Report. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2109-2119.	0.5	189
23	Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer. <i>Annals of Oncology</i> , 2018, 29, 953-958.	0.6	184
24	The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1409-1424.	0.5	182
25	Expression of thyroid transcription factor-1 in the spectrum of neuroendocrine cell lung proliferations with special interest in carcinoids. <i>Human Pathology</i> , 2002, 33, 175-182.	1.1	176
26	Thyroid transcription factor 1 and cytokeratins 1, 5, 10, 14 (34 $\beta$ E12) expression in basaloid and large-cell neuroendocrine carcinomas of the lung. <i>Human Pathology</i> , 2001, 32, 918-925.	1.1	173
27	The P16/cyclin D1/Rb pathway in neuroendocrine tumors of the lung. <i>Human Pathology</i> , 2003, 34, 136-142.	1.1	149
28	Intermittent Hypoxia Induces Early Functional Cardiovascular Remodeling in Mice. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 177, 227-235.	2.5	149
29	Expression of VEGF, semaphorin SEMA3F, and their common receptors neuropilins NP1 and NP2 in preinvasive bronchial lesions, lung tumours, and cell lines. <i>Journal of Pathology</i> , 2003, 200, 336-347.	2.1	142
30	Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfILER trial. <i>Annals of Oncology</i> , 2019, 30, 757-765.	0.6	129
31	SMARCA4-deficient Thoracic Sarcomas. <i>American Journal of Surgical Pathology</i> , 2019, 43, 455-465.	2.1	123
32	Cytopathologic Detection of Circulating Tumor Cells Using the Isolation by Size of Epithelial Tumor Cell Method. <i>American Journal of Clinical Pathology</i> , 2011, 135, 146-156.	0.4	122
33	Abnormal Expression of the Pre-mRNA Splicing Regulators SRSF1, SRSF2, SRPK1 and SRPK2 in Non Small Cell Lung Carcinoma. <i>PLoS ONE</i> , 2012, 7, e46539.	1.1	119
34	Morphological analysis of circulating tumour cells in patients undergoing surgery for non-small cell lung carcinoma using the isolation by size of epithelial tumour cell (ISET) method. <i>Cytopathology</i> , 2012, 23, 30-38.	0.4	117
35	Rapid On-Site Evaluation of Endobronchial Ultrasound-Guided Transbronchial Needle Aspirations for the Diagnosis of Lung Cancer: A Perspective From Members of the Pulmonary Pathology Society. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 253-262.	1.2	116
36	Mucinous Cells in Type 1 Pulmonary Congenital Cystic Adenomatoid Malformation as Mucinous Bronchioloalveolar Carcinoma Precursors. <i>American Journal of Surgical Pathology</i> , 2007, 31, 961-969.	2.1	113

#	ARTICLE	IF	CITATIONS
37	Pleuro-pulmonary Solitary Fibrous Tumors. American Journal of Surgical Pathology, 2008, 32, 1627-1642.	2.1	113
38	On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas. Lung Cancer, 2014, 83, 168-173.	0.9	113
39	The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases. Journal of Thoracic Oncology, 2017, 12, 334-346.	0.5	113
40	The Inflammatory Preatherosclerotic Remodeling Induced by Intermittent Hypoxia Is Attenuated by RANTES/CCL5 Inhibition. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 724-731.	2.5	109
41	Cell Cycle Regulators and Outcome of Adjuvant Cisplatin-Based Chemotherapy in Completely Resected Non-Small-Cell Lung Cancer: The International Adjuvant Lung Cancer Trial Biologic Program. Journal of Clinical Oncology, 2007, 25, 2735-2740.	0.8	107
42	Programmed Death Ligand-1 Immunohistochemistry: A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society. Archives of Pathology and Laboratory Medicine, 2016, 140, 341-344.	1.2	107
43	The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer. Journal of Thoracic Oncology, 2020, 15, 1434-1448.	0.5	107
44	EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach. Journal of Thoracic Oncology, 2020, 15, 29-49.	0.5	106
45	New Insights into the Molecular Characteristics of Pulmonary Carcinoids and Large Cell Neuroendocrine Carcinomas, and the Impact on Their Clinical Management. Journal of Thoracic Oncology, 2018, 13, 752-766.	0.5	102
46	Differential expression of telomerase reverse transcriptase (hTERT) in lung tumours. British Journal of Cancer, 2004, 90, 1222-1229.	2.9	97
47	Biomarker Testing in Lung Carcinoma Cytology Specimens: A Perspective From Members of the Pulmonary Pathology Society. Archives of Pathology and Laboratory Medicine, 2016, 140, 1267-1272.	1.2	95
48	Pulmonary preneoplasia: sequential molecular carcinogenetic events. Histopathology, 2009, 54, 43-54.	1.6	88
49	Course and prognosis of basaloid squamous cell carcinoma of the head and neck: A case-control study of 62 patients. European Journal of Cancer, 2008, 44, 244-250.	1.3	87
50	Open lung biopsy in nonresolving ARDS frequently identifies diffuse alveolar damage regardless of the severity stage and may have implications for patient management. Intensive Care Medicine, 2015, 41, 222-230.	3.9	85
51	Pulmonary involvement by Niemann-Pick disease. A report of six cases. Histopathology, 2006, 48, 596-603.	1.6	83
52	Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas. Human Pathology, 2016, 52, 9-18.	1.1	80
53	Comorbidities and Charlson score in resected stage I nonsmall cell lung cancer. European Respiratory Journal, 2005, 26, 480-486.	3.1	77
54	High-throughput somatic mutation profiling in pulmonary sarcomatoid carcinomas using the LungCarta Panel: exploring therapeutic targets. Annals of Oncology, 2015, 26, 1748-1753.	0.6	76

#	ARTICLE	IF	CITATIONS
55	The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade. <i>Annals of Oncology</i> , 2017, 28, 1934-1941.	0.6	76
56	Lung carcinomas with a basaloid pattern: a study of 90 cases focusing on their poor prognosis. <i>European Respiratory Journal</i> , 2008, 31, 854-859.	3.1	75
57	Differentiating pre- and minimally invasive from invasive adenocarcinoma using CT-features in persistent pulmonary part-solid nodules in Caucasian patients. <i>European Journal of Radiology</i> , 2015, 84, 738-744.	1.2	74
58	Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens. <i>European Respiratory Review</i> , 2017, 26, 170007.	3.0	74
59	Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC. <i>Journal of Experimental and Clinical Cancer Research</i> , 2011, 30, 57.	3.5	71
60	Telomere Shortening and Telomerase Reverse Transcriptase Expression in Preinvasive Bronchial Lesions. <i>Clinical Cancer Research</i> , 2005, 11, 2074-2082.	3.2	70
61	Telomerase expression in lung preneoplasia and neoplasia. <i>International Journal of Cancer</i> , 2007, 120, 1835-1841.	2.3	70
62	Immunohistochemistry of Pulmonary Biomarkers: A Perspective From Members of the Pulmonary Pathology Society. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 408-419.	1.2	70
63	Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey. <i>European Journal of Cancer</i> , 2018, 93, 37-46.	1.3	69
64	New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1189-1203.	0.5	68
65	Value of immunohistochemical markers in preinvasive bronchial lesions in risk assessment of lung cancer. <i>Clinical Cancer Research</i> , 2003, 9, 2195-203.	3.2	65
66	Liquid Biopsy in Lung Cancer: A Perspective From Members of the Pulmonary Pathology Society. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 825-829.	1.2	64
67	Erdheim-Chester Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1998, 157, 650-653.	2.5	62
68	Cigarette Smoking, Preinvasive Bronchial Lesions, and Autofluorescence Bronchoscopy. <i>Chest</i> , 2002, 122, 1902-1908.	0.4	62
69	34 $\beta$ E12 expression along the whole spectrum of neuroendocrine proliferations of the lung, from neuroendocrine cell hyperplasia to small cell carcinoma. <i>Histopathology</i> , 2003, 42, 156-166.	1.6	62
70	Statin-induced fibrotic nonspecific interstitial pneumonia. <i>European Respiratory Journal</i> , 2002, 19, 577-580.	3.1	61
71	New molecular classification of large cell neuroendocrine carcinoma and small cell lung carcinoma with potential therapeutic impacts. <i>Translational Lung Cancer Research</i> , 2020, 9, 2233-2244.	1.3	58
72	CT characteristics of resolving ground-glass opacities in a lung cancer screening programme. <i>European Journal of Radiology</i> , 2011, 77, 410-416.	1.2	55

#	ARTICLE	IF	CITATIONS
73	Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions. <i>EBioMedicine</i> , 2019, 48, 191-202.	2.7	55
74	Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC. <i>Targeted Oncology</i> , 2015, 10, 247-253.	1.7	54
75	French multicentric validation of <i>ALK</i> rearrangement diagnostic in 547 lung adenocarcinomas. <i>European Respiratory Journal</i> , 2015, 46, 207-218.	3.1	54
76	Chemoprevention of lung cancer. <i>Lancet Oncology</i> , The, 2003, 4, 659-669.	5.1	52
77	Diagnosis of Acute Cellular Rejection and Antibody-Mediated Rejection on Lung Transplant Biopsies: A Perspective From Members of the Pulmonary Pathology Society. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 437-444.	1.2	52
78	Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma. <i>Journal of Thoracic Disease</i> , 2019, 11, S89-S101.	0.6	52
79	Osteoblastic Reaction in Non-small Cell Lung Carcinoma and its Association to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Response and Prolonged Survival. <i>Journal of Thoracic Oncology</i> , 2010, 5, 491-496.	0.5	51
80	Unusual cystic presentation of pulmonary nodular amyloidosis associated with MALT-type lymphoma. <i>European Respiratory Journal</i> , 2007, 30, 589-592.	3.1	50
81	Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort. <i>Clinical Lung Cancer</i> , 2019, 20, e564-e575.	1.1	49
82	c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1962-1967.	0.5	48
83	NCAM (Neural Cell Adhesion Molecules) expression in malignant mesotheliomas. <i>Human Pathology</i> , 2000, 31, 415-421.	1.1	47
84	<i>MET</i> exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung. <i>Oncotarget</i> , 2017, 8, 42428-42437.	0.8	47
85	Telomere shortening is correlated with the DNA damage response and telomeric protein down-regulation in colorectal preneoplastic lesions. <i>Annals of Oncology</i> , 2008, 19, 1875-1881.	0.6	45
86	Multifocal alveolar hyperplasia associated with lymphangioleiomyomatosis in tuberous sclerosis. <i>Histopathology</i> , 1997, 30, 570-575.	1.6	44
87	Adequacy of CT-guided biopsies with histomolecular subtyping of pulmonary adenocarcinomas: Influence of ATS/ERS/IASLC guidelines. <i>Lung Cancer</i> , 2013, 82, 69-75.	0.9	44
88	Lung Squamous Cell Carcinomas with Basaloid Histology Represent a Specific Molecular Entity. <i>Clinical Cancer Research</i> , 2014, 20, 5777-5786.	3.2	44
89	<i>PARD3</i> Inactivation in Lung Squamous Cell Carcinomas Impairs STAT3 and Promotes Malignant Invasion. <i>Cancer Research</i> , 2015, 75, 1287-1297.	0.4	44
90	ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 116, 15-24.	0.9	44

#	ARTICLE	IF	CITATIONS
91	Usual interstitial pneumonia end-stage features from explants with radiologic and pathological correlations. <i>Annals of Diagnostic Pathology</i> , 2015, 19, 269-276.	0.6	43
92	Metastases from bronchioloalveolar carcinomas associated with long-standing type 1 congenital cystic adenomatoid malformations. A report of two cases. <i>Histopathology</i> , 2006, 48, 204-206.	1.6	42
93	Reclassification of Neuroendocrine Tumors Improves the Separation of Carcinoids and the Prediction of Survival. <i>Journal of Thoracic Oncology</i> , 2008, 3, 1410-1415.	0.5	42
94	Case Report. Pulmonary Involvement in Niemann-Pick Disease Subtype B: CT Findings. <i>Journal of Computer Assisted Tomography</i> , 1996, 20, 990-992.	0.5	41
95	Comprehensive Molecular and Pathologic Evaluation of Transitional Mesothelioma Assisted by Deep Learning Approach: A Multi-Institutional Study of the International Mesothelioma Panel from the MESOPATH Reference Center. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1037-1053.	0.5	40
96	Cytoplasmic Cellular Structures Control Permeability of Outer Mitochondrial-Membrane for ADP and Oxidative-Phosphorylation in Rat-Liver Cells. <i>Biochemical and Biophysical Research Communications</i> , 1995, 213, 138-146.	1.0	38
97	Clinical prognostic indicators of high-grade pre-invasive bronchial lesions. <i>European Respiratory Journal</i> , 2004, 24, 24-29.	3.1	37
98	Lung adenocarcinomas: correlation of computed tomography and pathology findings. <i>Diagnostic and Interventional Imaging</i> , 2016, 97, 955-963.	1.8	37
99	Mucinous cystadenoma of the lung. <i>Cancer</i> , 1995, 76, 1540-1544.	2.0	36
100	Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small cell lung cancer. <i>Molecular Oncology</i> , 2014, 8, 555-564.	2.1	36
101	Telomere Maintenance and DNA Damage Responses during Lung Carcinogenesis. <i>Clinical Cancer Research</i> , 2010, 16, 2979-2988.	3.2	34
102	Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung. <i>Journal of Thoracic Oncology</i> , 2018, 13, 205-217.	0.5	33
103	EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease. <i>European Journal of Cancer</i> , 2019, 122, 109-114.	1.3	33
104	Placental transmogrification of the lung: clinicopathologic, immunohistochemical and molecular study of two cases, with particular emphasis on the interstitial clear cells. <i>Human Pathology</i> , 2004, 35, 517-521.	1.1	32
105	Expression of candidate tumor suppressor gene ING2 is lost in non-small cell lung carcinoma. <i>Lung Cancer</i> , 2010, 69, 180-186.	0.9	32
106	Primary lung adenocarcinoma: characteristics by smoking habit and sex. <i>European Respiratory Journal</i> , 2011, 38, 1412-1419.	3.1	29
107	PL04a.04: Multicentric French Harmonization Study for PD-L1 IHC Testing in NSCLC. <i>Journal of Thoracic Oncology</i> , 2017, 12, S11-S12.	0.5	29
108	Molecular and Immune Biomarkers in Acute Respiratory Distress Syndrome: A Perspective From Members of the Pulmonary Pathology Society. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 1719-1727.	1.2	29



#	ARTICLE	IF	CITATIONS
109	Imaging of Tumors of the Trachea and Central Bronchi. <i>Radiologic Clinics of North America</i> , 2009, 47, 227-241.	0.9	27
110	Determining the profiles and parameters for gene amplification testing of growth factor receptors in lung cancer. <i>International Journal of Cancer</i> , 2013, 133, 898-907.	2.3	27
111	Transbronchial Lung Cryobiopsy for Interstitial Lung Disease Diagnosis: A Perspective From Members of the Pulmonary Pathology Society. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 1281-1284.	1.2	26
112	A Recombinant Fungal Lectin for Labeling Truncated Glycans on Human Cancer Cells. <i>PLoS ONE</i> , 2015, 10, e0128190.	1.1	25
113	Release of c-FLIP brake selectively sensitizes human cancer cells to TLR3-mediated apoptosis. <i>Cell Death and Disease</i> , 2018, 9, 874.	2.7	22
114	Interobserver variation in the assessment of the sarcomatoid and transitional components in biphasic mesotheliomas. <i>Modern Pathology</i> , 2020, 33, 255-262.	2.9	22
115	Adenocarcinoma of the lung mimicking inflammatory lung disease with honeycombing. <i>European Respiratory Journal</i> , 2004, 24, 502-505.	3.1	20
116	Nuclear translocation of IGF1R by intracellular amphiregulin contributes to the resistance of lung tumour cells to EGFR-TKI. <i>Cancer Letters</i> , 2018, 420, 146-155.	3.2	20
117	Malakoplakia of the Neck. <i>JAMA Otolaryngology</i> , 2003, 129, 1240.	1.5	18
118	CT-guided Biopsy of Nonresolving Focal Air Space Consolidation. <i>Journal of Thoracic Imaging</i> , 2008, 23, 7-12.	0.8	18
119	CT-texture analysis of subsolid nodules for differentiating invasive from in-situ and minimally invasive lung adenocarcinoma subtypes. <i>Diagnostic and Interventional Imaging</i> , 2018, 99, 291-299.	1.8	18
120	Why technical aspects rather than biology explain cellular heterogeneity in ALK-positive non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2012, 4, 240-1.	0.6	18
121	Wholistic approach: Transcriptomic analysis and beyond using archival material for molecular diagnosis. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 382-393.	1.5	18
122	An "Anaplastic" Kaposi's Sarcoma Mimicking a Stewart-Treves Syndrome. A Case Report and a Review of Literature. <i>American Journal of Dermatopathology</i> , 2008, 30, 265-268.	0.3	17
123	Second/third-line nivolumab vs nivo plus ipilimumab in malignant pleural mesothelioma: Long-term results of IFCT-1501 MAPS2 phase IIR trial with a focus on hyperprogression (HPD). <i>Annals of Oncology</i> , 2019, 30, v747.	0.6	17
124	Pulmonary Nodules with the CT Halo Sign. <i>Respiration</i> , 2002, 69, 103-106.	1.2	16
125	Telomerase activity in proximal and distal gastric neoplastic and preneoplastic lesions using immunohistochemical detection of hTERT. <i>Digestive and Liver Disease</i> , 2005, 37, 439-445.	0.4	16
126	Mucinous adenocarcinoma arising in congenital pulmonary airway malformation: clinicopathological analysis of 37 cases. <i>Histopathology</i> , 2021, 78, 434-444.	1.6	16



#	ARTICLE	IF	CITATIONS
127	Dramatic Improvement in Survival After Lung Transplantation Over Time: A Single Center Experience. <i>Transplantation Proceedings</i> , 2009, 41, 687-691.	0.3	15
128	Second or 3rd line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Updated results of the IFCT-1501 MAPS2 randomized phase 2 trial. <i>Annals of Oncology</i> , 2017, 28, v648.	0.6	15
129	Cisplatin unleashes Toll-like receptor 3-mediated apoptosis through the downregulation of c-FLIP in malignant mesothelioma. <i>Cancer Letters</i> , 2020, 472, 29-39.	3.2	15
130	Stapled peptide targeting the CDK4/Cyclin D interface combined with Abemaciclib inhibits KRAS mutant lung cancer growth. <i>Theranostics</i> , 2020, 10, 2008-2028.	4.6	15
131	PD-L1 Testing for Immune Checkpoint Inhibitors in Mesothelioma: For Want of Anything Better?. <i>Journal of Thoracic Oncology</i> , 2017, 12, 778-781.	0.5	14
132	Glut-1 intensity and pattern of expression in thymic epithelial tumors are predictive of WHO subtypes. <i>Pathology Research and Practice</i> , 2015, 211, 996-1002.	1.0	13
133	OA03.03 Phase 2B of Blueprint PD-L1 Immunohistochemistry Assay Comparability Study. <i>Journal of Thoracic Oncology</i> , 2018, 13, S325.	0.5	13
134	Interobserver Reliability of Programmed Cell Death Ligand-1 Scoring Using the VENTANA PD-L1 (SP263) Assay in NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 550-555.	0.5	13
135	The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 686-696.	0.5	13
136	Value of cardiac MRI in peripartum cardiomyopathy. <i>Archives of Cardiovascular Diseases</i> , 2011, 104, 263-264.	0.7	12
137	Prospective Multicenter Validation of the Detection of ALK Rearrangements of Circulating Tumor Cells for Noninvasive Longitudinal Management of Patients With Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 807-816.	0.5	11
138	Wegener Granulomatosis Revealed by Pleural Effusion. <i>Case Reports in Medicine</i> , 2009, 2009, 1-3.	0.3	9
139	Giant intracardiac neoplastic thrombus of a large cell neuroendocrine carcinoma of the lung. <i>Cardiovascular Pathology</i> , 2010, 19, e85-e87.	0.7	9
140	Personalized chemotherapy of lung cancer: What the radiologist should know. <i>Diagnostic and Interventional Imaging</i> , 2016, 97, 287-296.	1.8	9
141	P2.09-17 Real-World Concordance Across Pathologists for PD-L1 Scoring in Non-Small Cell Lung Cancer: Results from a Large Nationwide Initiative. <i>Journal of Thoracic Oncology</i> , 2019, 14, S775.	0.5	9
142	Percutaneous CT-guided biopsy of lytic bone lesions in patients clinically suspected of lung cancer: Diagnostic performances for pathological diagnosis and molecular testing. <i>Lung Cancer</i> , 2020, 140, 93-98.	0.9	9
143	Prognostic biomarkers in non-small-cell lung carcinoma. <i>Current Diagnostic Pathology</i> , 2006, 12, 418-428.	0.4	8
144	NUT carcinoma of the lung. <i>Seminars in Diagnostic Pathology</i> , 2021, 38, 72-82.	1.0	8

#	ARTICLE	IF	CITATIONS
145	Diagnosis of cardiac tumors: Contribution of non-invasive cardiac imaging in routine practice. <i>International Journal of Cardiology</i> , 2012, 157, 298-300.	0.8	7
146	Fishing for ALK with immunohistochemistry may predict response to crizotinib. <i>Tumori</i> , 2013, 99, e229-e232.	0.6	7
147	EORTC-ETOP randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab versus placebo for patients with early stage non-small cell lung cancer (NSCLC) after resection and standard adjuvant chemotherapy: PEARLS (NCT02504372).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS8571-TPS8571.	0.8	7
148	Effect of Lung Volume and Gravity on the Attenuation and Size of a Pure Ground-Glass Nodule. <i>Journal of Thoracic Imaging</i> , 2012, 27, W15-W17.	0.8	6
149	Clinical relevance of ROS1 rearrangements detection in advanced squamous cell carcinomas. <i>Lung Cancer</i> , 2016, 102, 42-43.	0.9	6
150	Validation of the QR1 Antibody for the Evaluation of PD-L1 Expression in Non-“Small Cell Lung Adenocarcinomas. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, 23-29.	0.6	6
151	Detection of acquired TERT amplification in addition to predisposing p53 and Rb pathways alterations in EGFR-mutant lung adenocarcinomas transformed into small-cell lung cancers. <i>Lung Cancer</i> , 2022, 167, 98-106.	0.9	6
152	NSCLC Subtyping in Conventional Cytology: Results of the International Association for the Study of Lung Cancer Cytology Working Group Survey to Determine Specific Cytomorphologic Criteria for Adenocarcinoma and Squamous Cell Carcinoma. <i>Journal of Thoracic Oncology</i> , 2022, 17, 793-805.	0.5	6
153	Exercise in lung Cancer, the healthcare providers opinion (E.C.H.O.): Results of the EORTC lung cancer Group (LCG) survey. <i>Lung Cancer</i> , 2022, 169, 94-101.	0.9	6
154	PD2-3-4: Prognostic and predictive value of apoptosis related factors Fas, FasL and survivin in non small cell lung carcinoma patients enrolled in the IALT Trial. <i>Journal of Thoracic Oncology</i> , 2007, 2, S444-S445.	0.5	5
155	Chest pains complicating an artificial therapeutic pneumothorax. <i>European Respiratory Journal</i> , 1997, 10, 2659-2661.	3.1	4
156	Impact of Molecular Pathology on the Clinical Management of Lung Cancer. <i>Respiration</i> , 2005, 72, 229-232.	1.2	4
157	Hemorrhagic Tamponade Due to Cardiac Angiosarcoma. <i>Southern Medical Journal</i> , 2010, 103, 1055-1057.	0.3	4
158	Multiple Microthrombi on a Papillary Fibroelastoma of the Aortic Valve. <i>Annals of Thoracic Surgery</i> , 2012, 93, 304-306.	0.7	4
159	Benfluorex: An active toxin for the development of aortic valve stenosis. <i>International Journal of Cardiology</i> , 2015, 181, 328-330.	0.8	4
160	Drug-induced aortic valve stenosis: An under recognized entity. <i>International Journal of Cardiology</i> , 2016, 220, 429-434.	0.8	4
161	MA25.01 EORTC Lung Cancer Group Survey to Define Synchronous Oligometastatic Disease in NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, S445-S446.	0.5	4
162	Pathological central review of 290 thymic epithelial tumors (TET): The national network RYTHMIC experience.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8568-8568.	0.8	4

#	ARTICLE	IF	CITATIONS
163	P2.09-24 IASLC Global Survey for Pathologists on PD-L1 Testing for Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, S778-S779.	0.5	3
164	Selected highlights of the 2019 Pulmonary Pathology Society Biennial Meeting: PD-L1 test harmonization studies. <i>Translational Lung Cancer Research</i> , 2020, 9, 906-916.	1.3	3
165	Abstract 2038: A novel role for the NLRP3 inflammasome in lung cancer. , 2015, , .		3
166	Telomerase activation in adenocarcinoma-bronchioloalveolar carcinoma. <i>European Respiratory Journal</i> , 2006, 27, 1079-1081.	3.1	2
167	Twenty-two cutaneous primary melanomas in a patient with high genetic predisposition to melanoma receiving levodopa therapy for Parkinson's disease. <i>Pigment Cell and Melanoma Research</i> , 2009, 22, 851-853.	1.5	2
168	Rare case study of a primary carcinoma of the petrous bone and a brief literature review. <i>Head and Neck</i> , 2015, 37, E45-8.	0.9	2
169	P3.01-021 Reproducibility of Comprehensive Histologic Assessment and Refining Histologic Criteria in P Staging of Multiple Tumor Nodules. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1131-S1132.	0.5	2
170	Compliance to regional recommendations for molecular analyses and management of advanced lung cancer patients. <i>Future Oncology</i> , 2019, 15, 2139-2149.	1.1	2
171	MA21.03 The International Association for the Study of Lung Cancer (IASLC) Global Survey on Molecular Testing in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, S335-S336.	0.5	2
172	Precision medicine at its best: Prolonged survival in a child presenting a secondary mesothelioma treated with crizotinib. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28666.	0.8	2
173	Predicting Response to Programmed Cell Death Protein-1 or Programmed Death-Ligand 1 Blockade in NSCLC's Multiplex Immunohistochemistry or Immunofluorescence the Answer?. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1247-1249.	0.5	2
174	Abstract 2320: CD70 immune checkpoint ligand is associated with the epithelial-to-mesenchymal transition in non-small cell lung cancer. , 2016, , .		2
175	Neuroendocrine Neoplasms. , 2008, , 563-577.		2
176	Large cell carcinoma and adenosquamous carcinoma of the lung. , 0, , 1114-1126.		1
177	Diagnostic and therapeutic strategies for elderly patients with advanced non-small cell lung cancer (NSCLC): Results from an EORTC pan-European survey. <i>Annals of Oncology</i> , 2017, 28, v490.	0.6	1
178	Neuroendocrine Neoplasms. , 2018, , 552-566.		1
179	MA12.01 Redefining Malignant Pleural Mesothelioma Types as a Continuum Uncovers Immune-Vascular Interactions. <i>Journal of Thoracic Oncology</i> , 2019, 14, S295.	0.5	1
180	Abstract 5358: Multi-omics comparative analyses of pulmonary typical carcinoids, atypical carcinoids, and large-cell neuroendocrine carcinoma. , 2018, , .		1

#	ARTICLE	IF	CITATIONS
181	Editor's Note: Loss of Histone H4K20 Trimethylation Occurs in Preneoplasia and Influences Prognosis of Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1776-1776.	3.2	1
182	What Is a Neuroendocrine Tumor?. <i>American Journal of Surgical Pathology</i> , 2000, 24, 319.	2.1	0
183	Lobular distributed ground-glass opacification due to metastatic cardiac angiosarcoma. <i>European Journal of Radiology Extra</i> , 2007, 64, 59-62.	0.1	0
184	B7-01: Aberrant pattern of histone H4 modification in human lung carcinoma. <i>Journal of Thoracic Oncology</i> , 2007, 2, S354.	0.5	0
185	D4-03: SCF protein (Skp2, CUL1) regulate the E2F1 dependent transcriptional activity and cyclin E in human lung tumors. <i>Journal of Thoracic Oncology</i> , 2007, 2, S400-S401.	0.5	0
186	An Uncommon Cause of Renovascular Hypertension. <i>Canadian Journal of Cardiology</i> , 2012, 28, 397.e1-397.e3.	0.8	0
187	Diseases of the pleura. , 0, , 1408-1564.		0
188	Expérience de la tÃ©lÃ©pathologie pour la certification diagnostique du mÃ©sothÃ©liome. <i>Revue Francophone Des Laboratoires</i> , 2015, 2015, 57-65.	0.0	0
189	PUB015 The Use of Immunohistochemistry Improves the Diagnosis of SCLC. An International Reproducibility Study in a Demanding Set of Cases. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1454-S1455.	0.5	0
190	ES08.02 Immunotherapy. <i>Journal of Thoracic Oncology</i> , 2018, 13, S203-S204.	0.5	0
191	MS17.03 Quantitative Image Analysis, Image-Based Profiling Including 3D Digital Printing and AI. <i>Journal of Thoracic Oncology</i> , 2019, 14, S190-S191.	0.5	0
192	O.04 Results from the IASLC Global Survey on Molecular Testing in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, S1153-S1154.	0.5	0
193	MA08.02 Durvalumab Impact in the Treatment Strategy of Stage III Non-Small Cell Lung Cancer (NSCLC): An EORTC Young Investigator Lung Cancer Group Survey. <i>Journal of Thoracic Oncology</i> , 2019, 14, S277-S278.	0.5	0
194	Abstract 3940: Inactivation of the PARD3 gene is a recurrent event in lung squamous cell carcinomas and affects STAT3 activity and tumor invasiveness. , 2015, , .		0
195	Pathology and molecular biology of lung cancer. , 2019, , 447-452.		0